戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 antially reduced level of inhibition against HIV integrase.
2 rs active against mammalian topoisomerase or HIV integrase.
3 hesized which have improved activity against HIV integrase.
4 ruplexes exhibit inhibitory activity against HIV integrase.
5 anspositional recombination, such as that of HIV integrase.
6 embles RSS cleavage and 3' end processing by HIV integrase and Mu transposase in that these reactions
7 lexibility and conformational preferences of HIV integrase and to (2) study raltegravir binding in th
8 r (LEDGF/p75) binds both chromosomal DNA and HIV integrase, and might therefore direct integration by
9                                Inhibitors of HIV integrase are currently being sought as potential ne
10 gravir, an antiretroviral agent that targets HIV integrase, as a pharmacologic inhibitor of ALDOA-gam
11 tly approved antiviral compound that targets HIV integrase, can inhibit the nuclease function of huma
12                                              HIV integrase catalyses the incorporation of virally der
13       However, published X-ray structures of HIV integrase do not include the DNA; thus, there is a n
14                                          The HIV integrase enzyme (IN) catalyzes the initial DNA brea
15                Human immunodeficiency virus (HIV) integrase enzyme is required for the integration of
16 re, although clinically useful inhibitors of HIV integrase have been developed, their mechanism of ac
17                                  A series of HIV integrase (HIV-1 IN) inhibitors were synthesized to
18 of divalent ion dependent strand transfer by HIV integrase in antiviral therapy.
19  primary requirement for inhibition of HIV-1 HIV integrase (IN) activity.
20 o-hybrid screen as an interaction partner of HIV integrase (IN) and in two independent siRNA screens
21 has been implicated in inhibiting homologous HIV integrase (IN) and influenza endonuclease via metal
22  discovery has been increasingly focusing on HIV integrase (IN) as a potential therapeutic target.
23                                              HIV integrase (IN) catalyzes the insertion into the geno
24 o determine the architectures of full-length HIV integrase (IN) dimers in solution.
25 n IBD overlaps with the binding site for the HIV integrase (IN), and IN was capable of efficiently se
26 s step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN).
27  inhibitors of human immunodeficiency virus (HIV) integrase (IN).
28 l DNA into the host genome is carried out by HIV-integrase (IN) and is a critical step in viral repli
29  A long-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is current
30                                          The HIV integrase inhibitor d[G(3)(TG(3))(3)] forms an extre
31  trial comparing three-drug ART based on the HIV integrase inhibitor dolutegravir with standard care
32  synthesis of a complex chiral atropisomeric HIV integrase inhibitor has been accomplished.
33 or protease (Mpro) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the poten
34 ction between boceprevir and raltegravir, an HIV integrase inhibitor.
35  leads for the development of a new class of HIV integrase inhibitor.
36 ravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in
37 riority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator rito
38 sessed the prevalence of PDDIs in the era of HIV integrase inhibitors (INIs), characterized by more f
39  structural leads for the development of new HIV integrase inhibitors which do not rely on this poten
40 te inhibitors were quinolone antibiotics and HIV integrase inhibitors, which share common structural
41  in the era of human immunodeficiency virus (HIV) integrase inhibitors (INIs), characterized by more
42 -benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed.
43                                              HIV integrase is essential for HIV replication.
44 or (LEDGF) and human immunodeficiency virus (HIV) integrase is an important possible strategy for ant
45  unintegrated DNA likely contributed to SV40-HIV integrase mutant replication.
46 t the direct interaction between TRN-SR2 and HIV integrase predominantly involves the catalytic core
47                   Unlabelled RAP1 GTPase and HIV integrase proteins were selectively detected from va
48 two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vi
49                                          The HIV integrase strand transfer inhibitor elvitegravir (EV
50                                     Specific HIV integrase strand transfer inhibitors are thought to
51 e we present the discovery of a new class of HIV integrase strand transfer inhibitors based on the 2-
52                   Although second-generation HIV integrase strand-transfer inhibitors (INSTIs) are pr
53      As use of human immunodeficiency virus (HIV) integrase strand transfer inhibitors (INSTI) increa
54  nanomolar IC(50) values were achieved in an HIV-integrase strand transfer assay with both carboxylic
55 w "minor" polymorphisms and substitutions in HIV integrase that are associated with these subtypes ca
56                                              HIV integrase, the enzyme that inserts the viral DNA int
57 ain antibody mimics the effect of binding of HIV integrase to LEDGF which is crucial for HIV propagat
58 rst described as 'foldback' reversal for the HIV integrase, was also observed upon disassembly/reasse
59 es of L-chicoric acid, a potent inhibitor of HIV integrase, were studied.